FDA Approves COPAXONE — Teva Neuroscience, Inc.

Generics giant Teva Neuroscience announced the regulatory approval of its generic glatiramer acetate, bringing a widely used treatment for multiple sclerosis to market following the expiration of its patent protection. The approval is anticipated to trigger significant pricing erosion and increased competition, likely drawing heavy market share from Teva’s branded COPAXONE product.